35 / 43
Patients
•
Overall, 78 (21.6%) patients received 1L R/M nivolumab or IC after platinum-based therapy in the
primary/adjuvant setting
Efficacy
•
Among patients receiving 1L R/M nivolumab or IC after platinum-based therapy in the primary/adjuvant
setting, OS was improved with nivolumab vs IC
•
The 12-month OS rate was nearly 40% with nivolumab in this subgroup
•
Median PFS (95% CI) was 2.3 (1.9, 3.3) months for nivolumab and 2.3 (1.7, 3.2) months for IC
•
The ORR was higher with nivolumab vs IC (19.2% vs 11.5%)
35
Results: 1ºL R/M nivolumab or IC after platinum-
based therapy in the primary/adjuvant setting